PMID- 37950424
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240123
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 23
IP  - 12
DP  - 2023 Jul-Dec
TI  - Efficacy and toxicity of drugs targeting KRAS(G12C) mutation in non-small cell 
      lung cancer: a meta-analysis.
PG  - 1295-1303
LID - 10.1080/14737140.2023.2282606 [doi]
AB  - OBJECTIVE: To systematically analyze the efficacy and toxicity of drugs targeting 
      KRAS(G12C) mutation in non-small cell lung cancer (NSCLC). METHODS: The candidate 
      studies were identified in PubMed, Embase, Cochrane Library, CNKI, and Wanfang 
      databases up to 1 June 2023. Data on efficacy, prognosis, and adverse events 
      (AEs) were extracted and calculated by meta-analysis. RESULTS: Six eligible 
      prospective studies were included in this meta-analysis, including 563 patients 
      with advanced or metastatic NSCLC. For patients with NSCLC, the objective 
      response rate (ORR) of drugs targeting KRAS(G12C) mutation was 37% (95%CI 31-43), 
      median duration of response (DOR) was 8.89 months (95%CI 7.96-9.83), and median 
      progression-free survival (PFS) was 6.40 months (95%CI 5.86-6.93). The overall 
      incidence of AEs was 88% (95%CI 79-96) and the incidence of grade >/=3 AEs was 44% 
      (95%CI 24-64). The most common AEs were diarrhea, nausea, fatigue, and vomiting. 
      The most common grade >/=3 AEs were Alaninetransaminase (ALT) or 
      Aspartatetransaminase (AST) increased and diarrhea. CONCLUSION: Sotorasib, 
      Adagrasib, and Garsorasib as the drugs of choice for patients with KRAS(G12C) 
      mutation NSCLC, have definite efficacy and acceptable safety, especially for 
      patients with advanced or metastatic disease and within posterior line therapy.
FAU - Luo, Wei
AU  - Luo W
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
AD  - Department of Radiology, The First Affiliated Hospital of Chengdu Medical 
      College, Chengdu, Sichuan, China.
FAU - Zhu, Jing
AU  - Zhu J
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
AD  - Department of Radiology, The First Affiliated Hospital of Chengdu Medical 
      College, Chengdu, Sichuan, China.
FAU - Zhang, Wenxue
AU  - Zhang W
AD  - Department of Surgery, Guanghan Hospital of Traditional Medicine, Deyang, 
      Sichuan, China.
FAU - Yu, Airu
AU  - Yu A
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
FAU - Zhou, Wei
AU  - Zhou W
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
AD  - Department of Radiology, The First Affiliated Hospital of Chengdu Medical 
      College, Chengdu, Sichuan, China.
FAU - Xu, Ke
AU  - Xu K
AUID- ORCID: 0000-0002-5520-5754
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, Sichuan, China.
AD  - Department of Oncology, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231208
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - 0 (KRAS protein, human)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology
MH  - *Lung Neoplasms/drug therapy/genetics/pathology
MH  - Proto-Oncogene Proteins p21(ras)/genetics
MH  - Prospective Studies
MH  - Mutation
MH  - Diarrhea
OTO - NOTNLM
OT  - KRASG12C mutation
OT  - adverse events
OT  - efficacy
OT  - non-small cell lung cancer
OT  - prognosis
EDAT- 2023/11/11 11:46
MHDA- 2023/12/17 13:19
CRDT- 2023/11/11 01:13
PHST- 2023/12/17 13:19 [medline]
PHST- 2023/11/11 11:46 [pubmed]
PHST- 2023/11/11 01:13 [entrez]
AID - 10.1080/14737140.2023.2282606 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2023 Jul-Dec;23(12):1295-1303. doi: 
      10.1080/14737140.2023.2282606. Epub 2023 Dec 8.